Aptevo Therapeutics (APVO) Total Non-Current Liabilities (2015 - 2025)
Aptevo Therapeutics (APVO) posted Total Non-Current Liabilities of $9.8 million for Q4 2025, down 9.44% sequentially from $10.8 million in Q4 2024, and down 9.44% YoY from $10.8 million in Q4 2024.
Aptevo Therapeutics (APVO) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
Aptevo Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $9.8 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 9.44% year-over-year to $9.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.8 million (down 9.44% YoY) and the FY2025 annual result came in at $9.8 million, down 9.44% from the prior year.
- Total Non-Current Liabilities retreated to $9.8 million in Q4 2025 per APVO's latest filing, from $10.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $39.8 million in Q4 2021 and troughed at $9.8 million in Q4 2025.
- A 5-year average of $21.7 million and a median of $14.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities increased 7.91% in 2021, then slumped 59.2% in 2022.
- Over 5 years, Total Non-Current Liabilities stood at $39.8 million in 2021, then plunged by 59.2% to $16.2 million in 2022, then dropped by 22.29% to $12.6 million in 2023, then declined by 14.14% to $10.8 million in 2024, then slipped by 9.44% to $9.8 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.8 million, $10.8 million, and $10.7 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Aptevo Therapeutics | 3.19 Mn | -6.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.81 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 10.71 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Mar 31, 2024 | 11.51 Mn |
| Dec 31, 2023 | 12.62 Mn |
| Dec 31, 2022 | 16.24 Mn |
| Mar 31, 2022 | 27.73 Mn |
| Dec 31, 2021 | 39.81 Mn |
| Sep 30, 2021 | 38.00 Mn |
| Jun 30, 2021 | 37.06 Mn |
| Mar 31, 2021 | 36.08 Mn |
| Dec 31, 2020 | 36.95 Mn |
| Sep 30, 2020 | 35.22 Mn |
| Dec 31, 2019 | 41.57 Mn |
| Sep 30, 2019 | 40.80 Mn |
| Jun 30, 2019 | 39.92 Mn |
| Mar 31, 2019 | 41.70 Mn |
| Dec 31, 2018 | 36.89 Mn |
| Sep 30, 2018 | 34.59 Mn |